Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.40
$2.87
$2.35
$4.60
$21.24M1.1435,113 shs10,232 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$13.81
-0.2%
$9.88
$4.11
$28.68
$89.93M2.97173,169 shs23,706 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$7.04
+3.2%
$5.36
$3.13
$26.05
$101.70M2.69315,538 shs336,840 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$2.90
-0.3%
$1.97
$0.81
$3.11
$94.06M-0.09149,442 shs81,432 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%+1.27%-26.38%-16.96%-22.33%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%+12.73%+33.43%+134.86%+67,782.42%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
0.00%+28.16%+23.44%+84.67%-68.32%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+18.37%+55.91%+154.39%+145.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
1.5974 of 5 stars
3.35.00.00.00.00.00.0
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.5567 of 5 stars
3.54.00.00.00.61.70.6
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
1.8715 of 5 stars
3.53.00.00.00.61.70.0
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
1.8743 of 5 stars
3.53.00.00.00.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.50
Moderate Buy$12.00400.00% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00341.71% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3.00
Buy$59.25742.10% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00141.38% Upside

Current Analyst Ratings Breakdown

Latest DARE, OKYO, JSPR, and FBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/13/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
5/5/2025
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$25.91K819.79N/AN/A($0.69) per share-3.48
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$4.11 per shareN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.20) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)

Latest DARE, OKYO, JSPR, and FBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/13/2025Q1 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
5/12/2025Q1 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.17-$1.41-$0.24-$1.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.56
0.56
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
4.31
4.31
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.00%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
4.60%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
308.85 million8.50 millionNot Optionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2015.02 million14.33 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
733.84 million20.15 millionNot Optionable

Recent News About These Companies

OKYO moves toward FDA talks after eye drug trial – ICYMI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.41 +0.01 (+0.42%)
As of 07/3/2025 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$13.81 -0.03 (-0.22%)
Closing price 07/3/2025 03:25 PM Eastern
Extended Trading
$13.02 -0.80 (-5.76%)
As of 07/3/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$7.04 +0.22 (+3.17%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$6.90 -0.13 (-1.86%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$2.90 -0.01 (-0.34%)
Closing price 07/3/2025 03:00 PM Eastern
Extended Trading
$2.92 +0.02 (+0.66%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.